Aciphex

Aciphex

AciphexRecall

获取警报召回时。

Questions & Answers

副作用和不良反应

目前还没有warning information available for this product. We apologize for any inconvenience.

Legal Issues

目前尚无该药物可用的法律信息。

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

目前还没有manufacturer warning information available for this drug.

FDA Labeling Changes

目前,该药物尚无FDA标签更改。

Uses

Enter section text here

1.1 Healing of Erosive or Ulcerative GERD

Aciphex在短期治疗(4至8周)治疗方面,以侵蚀性或溃疡性胃食管反流疾病(GERD)的愈合和症状缓解。对于那些在治疗8周后未愈合的患者,可以考虑另外8周的ACIPHEX病程。

1.2 Maintenance of Healing of Erosive of Ulcerative GERD

ACIPHEX表示用于维持侵蚀性或溃疡性胃食管反流疾病(GERD维持)患者的胃灼热症状复发率的愈合和降低。对照研究不会延长超过12个月。

1.3 Treatment of Symptomatic GERD

ACIPHEX用于治疗白天和夜间胃灼热以及与成年人和青少年12岁及以上的GERD相关的其他症状。

1.4 Healing of Duodenal Ulcers

ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.

1.5 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with幽门螺杆菌infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate幽门螺杆菌。根除幽门螺杆菌has been shown to reduce the risk of duodenal ulcer recurrence. {SeeCLINICAL STUDIES(14.5) and剂量和给药(2.5)}

在治疗失败的患者中,应进行敏感性测试。如果证明对克拉霉素的耐药性或不可能进行敏感性测试,则应进行替代性抗菌治疗。{看CLINICAL PHARMACOLOGY, Microbiology(12.2) and the clarithromycin package insert,CLINICAL PHARMACOLOGY, Microbiology}

1.6病理性高分泌状况的治疗,包括Zollinger-Ellison综合征

o ACIPHEX表示长期治疗f pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

History

目前还没有drug history available for this drug.

其他信息

The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole sodium salt. It has an empirical formula of C18H20N3Nao3S and a molecular weight of 381.43. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural formula is:

化学结构的图像

Aciphex可作为延迟释放的,含有20毫克的Rabeprazole钠的肠涂层片。

Inactive ingredients of the 20 mg tablet are carnauba wax, crospovidone, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium stearate, mannitol, propylene glycol, sodium hydroxide, sodium stearyl fumarate, talc, and titanium dioxide. Iron oxide yellow is the coloring agent for the tablet coating. Iron oxide red is the ink pigment.

Aciphex制造商


  • 医生总保健公司。
    Aciphex(Rabeprazole Sodium) Tablet, Delayed Release [Physicians Total Care, Inc.]
  • Lake Erie Medical & Surgical Supply Dba Quality Care Produtcs Llc
    Aciphex(Rabeprazole钠)片剂,涂层[伊利湖医疗和外科供应DBA质量护理Produtcs LLC]
  • 伊利湖医疗和外科用品DBA质量护理产品有限责任公司
    Aciphex(Rabeprazole Sodium) Tablet, Coated [Lake Erie Medical & Surgical Supplies Dba Quality Care Products Llc]
  • 红衣主教健康
    Aciphex(Rabeprazole钠)片剂,涂层[Cardinal Health]
  • Bryant Ranch Prepack
    Aciphex(Rabeprazole钠)片剂,涂层[Bryant Ranch Prepack]
  • Carilion Materials Management
    Aciphex(Rabeprazole Sodium) Tablet, Delayed Release [Carilion Materials Management]
  • Eisai Inc.
    Aciphex(Rabeprazole Sodium) Tablet, Delayed Release [Eisai Inc.]

Login To Your Free Account

Baidu